SCYNEXIS Q2 net loss $13.3M, revenue $1.3M; cash runway into Q1 2024

SCYNEXIS INC

2022-Q2 EPS reported -$0.50 revenue$2,010,000

BREXAFEMME net revenue $1.3M in Q2 2022, up 86% from $0.7M in Q1.
Net loss $13.3M ($0.31/shr) vs net gain $1.7M ($0.06/shr) in Q2 2021.
Cash $118.7M at June 30, 2022; projected runway into Q1 2024.
FDA accepted sNDA for BREXAFEMME in recurrent VVC; PDUFA date Nov 30, 2022.
Total prescriptions up 29% QoQ to ~5,141; >2,200 HCPs prescribed in Q2.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.